Bellevue Group Ag 89bio, Inc. Transaction History

Bellevue Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $80,410 - $119,900	11,000 Added 80.29%	24,700 $197,000
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $52,845 - $89,505	-6,500 Reduced 32.18%	13,700 $159,000
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $126,540 - $304,570	-19,000 Reduced 48.47%	20,200 $225,000
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $391,560 - $504,660	-26,000 Reduced 39.88%	39,200 $605,000
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $25,470 - $39,654	-1,800 Reduced 2.69%	65,200 $1.24 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $702,160 - $1.13 Million	67,000 New	67,000 $1.02 Million

175

125M

84K

941K

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $491M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.